ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals Inc (RYTM)

51.90
1.88
(3.76%)
At close: July 15 4:00PM
51.90
-0.03
( -0.06% )
After Hours: 4:00PM

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
51.90
Bid
49.69
Ask
52.50
Volume
660,093
49.75 Day's Range 52.08
16.0101 52 Week Range 52.57
Market Cap
Previous Close
50.02
Open
50.39
Last Trade Time
16:53:47
Financial Volume
$ 33,456,177
VWAP
50.684
Average Volume (3m)
550,288
Shares Outstanding
60,972,909
Dividend Yield
-
PE Ratio
-17.14
Earnings Per Share (EPS)
-3.03
Revenue
77.43M
Net Profit
-184.68M

About Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals Inc is a biopharmaceutical company. It is focused on the development and commercialization of peptide therapeutics for the treatment of gastrointestinal, or GI, diseases, and genetic deficiencies that result in metabolic disorders. The company's product candidate is setmelanot... Rhythm Pharmaceuticals Inc is a biopharmaceutical company. It is focused on the development and commercialization of peptide therapeutics for the treatment of gastrointestinal, or GI, diseases, and genetic deficiencies that result in metabolic disorders. The company's product candidate is setmelanotide (RM 493), which is a potent, melanocortin 4, or MC4, receptor agonist for the treatment of rare genetic disorders of obesity caused by MC4 pathway deficiencies. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Wilmington, Delaware, USA
Founded
1970
Rhythm Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker RYTM. The last closing price for Rhythm Pharmaceuticals was $50.02. Over the last year, Rhythm Pharmaceuticals shares have traded in a share price range of $ 16.0101 to $ 52.57.

Rhythm Pharmaceuticals currently has 60,972,909 shares outstanding. The market capitalization of Rhythm Pharmaceuticals is $3.05 billion. Rhythm Pharmaceuticals has a price to earnings ratio (PE ratio) of -17.14.

Rhythm Pharmaceuticals (RYTM) Options Flow Summary

Overall Flow

Bullish

Net Premium

29k

Calls / Puts

100.00%

Buys / Sells

100.00%

OTM / ITM

0.00%

Sweeps Ratio

0.00%

RYTM Latest News

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

BOSTON, July 11, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their...

Rhythm Pharmaceuticals Announces Appointment of Alastair Garfield, Ph.D., as Chief Scientific Officer

BOSTON, July 08, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their...

Rhythm Pharmaceuticals Receives Positive CHMP Opinion for โ–ผIMCIVREEยฎ (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients between 2 and 6 years old with Bardet Biedl Syndrome or POMC, PCSK1, or LEPR Deficiency

- European Commission decision anticipated in the second half of 2024 - BOSTON, June 28, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
18.9120.725750174542.9952.0842.9944814146.55671554CS
49.5422.521246458942.3652.0839.45856842642.66611322CS
1213.5935.473766640638.3152.0835.1755028840.69736327CS
261230.075187969939.952.5735.1757804042.18232896CS
5235.71220.56825200716.1952.5716.010164266535.5246898CS
15633.1176.06382978718.852.573.0477155920.98113895CS
26030.82146.20493358621.0852.573.0458265521.52339348CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
WNWMeiwu Technology Company Ltd
$ 1.34
(50.56%)
3.44M
SVRESaverOne 2014 Ltd
$ 0.51
(14.84%)
2.9M
SIEBSiebert Financial Corporation
$ 1.97
(14.53%)
7.29k
SNTGSentage Holdings Inc
$ 2.78
(10.76%)
1.47k
ETONEton Pharmaceuticals Inc
$ 3.69
(10.48%)
219.34k
CYNCYNGN Inc
$ 7.84
(-14.60%)
139k
QLGNQualigen Therapeutics Inc
$ 0.345
(-10.78%)
383.84k
DJTTrump Media and Technology Group Corporation
$ 36.5439
(-9.95%)
2.57M
KTTAPasithea Therapeutics Corporation
$ 5.51
(-9.08%)
1.84k
DMACDiaMedica Therapeutics Inc
$ 3.2995
(-7.84%)
171
FFIEFaraday Future Intelligent Electric Inc
$ 0.5585
(8.40%)
7.83M
AAPLApple Inc
$ 234.40
(0.00%)
4.31M
TSLATesla Inc
$ 252.78
(0.06%)
4.15M
WNWMeiwu Technology Company Ltd
$ 1.34
(50.56%)
3.44M
MAXNMaxeon Solar Technologies Ltd
$ 0.223
(-1.76%)
3.19M

RYTM Discussion

View Posts
Monksdream Monksdream 5 months ago
RYTM new 52 week high
๐Ÿ‘๏ธ0
Monksdream Monksdream 5 months ago
RYTM new 52 week high

๐Ÿ‘๏ธ0
Monksdream Monksdream 7 months ago
RYTM new 52 week high
๐Ÿ‘๏ธ0
Monksdream Monksdream 8 months ago
RYTM new 52 week high
๐Ÿ‘๏ธ0
midastouch017 midastouch017 1 year ago
In my view ORMP is better than RYTM from investment perspective.

Sigh, how wrong can one be!
(including me - of course)
๐Ÿ‘๏ธ0
bandit007 bandit007 2 years ago
Why am I the only one posting here? This thing has been steady up over100% since I started posting here. Even on a day like today when most others are red. Another green day here!! $RYTM
๐Ÿ‘๏ธ0
bandit007 bandit007 2 years ago
When $20 breaks and holds this will fly! IMO
๐Ÿ‘๏ธ0
bandit007 bandit007 2 years ago
Looking like itโ€™s ready to move up again here. Possible bounce off of support.
๐Ÿ‘๏ธ0
Amatuer17 Amatuer17 2 years ago
Some you win some you lose - I had a lot of conviction but later lost faith after that time and sold completely.
๐Ÿ‘๏ธ0
Laszlo1 Laszlo1 2 years ago
Sorry
๐Ÿ‘๏ธ0
bandit007 bandit007 2 years ago
Thanks for posting. Breakout mode! GL
๐Ÿ‘๏ธ0
conix conix 2 years ago
RYTM Chart

๐Ÿ‘๏ธ0
bandit007 bandit007 2 years ago
Iโ€™m liking the chart on this one.
๐Ÿ‘๏ธ0
willlbone willlbone 2 years ago
Two year slide continues.
๐Ÿ‘๏ธ0
Amatuer17 Amatuer17 3 years ago
I lost money on RYTM and booked losses already.
๐Ÿ‘๏ธ0
midastouch017 midastouch017 3 years ago
In my view ORMP is better than
RYTM from investment perspective.

Spot on!
๐Ÿ‘๏ธ0
Amatuer17 Amatuer17 3 years ago
In my view ORMP is better than RYTM from investment perspective.

The current market capon $255 million allows it to be a 10 bagger ($2.55 B) - speciall that it has first in class product and huge unmet market.

RTYM also has first in class product with unmet needs but it is rare disease and not many outside US can afford
๐Ÿ‘๏ธ0
Amatuer17 Amatuer17 3 years ago
Agree - it is good company
Will take time to make money but proof of product is there.

The valuation is fair at this point - upside maybe 50-70% by end of the year based on how they price and are able show sale.

The payment cycle with insurance will be key as the product is very high priced -
๐Ÿ‘๏ธ0
fishhunter fishhunter 3 years ago
I started building a major position. And already a little green!
Quite the biotech soon last couple weeks= opportunity!
๐Ÿ‘๏ธ0
Amatuer17 Amatuer17 3 years ago
For some reason it is tanking now -sale the news
๐Ÿ‘๏ธ0
midastouch017 midastouch017 3 years ago
RYTM is not cheap as it has market cap of $832 million for pre-revenue biotech - so it is richly valued.


Are you kidding? You know what the mc is today?

Market Cap 1.737B

Since you introduced me to this company it has doubled
in price, if it was richly valued then, what is it now?

But this is besides my previous point - namely i 'missed'
the entry point.
๐Ÿ‘๏ธ0
Amatuer17 Amatuer17 3 years ago
You can actually wait for some time and buy - this is a long term play
๐Ÿ‘๏ธ0
midastouch017 midastouch017 3 years ago
I missed out this one!

๐Ÿ‘๏ธ0
Amatuer17 Amatuer17 3 years ago
Just amazing results - they are starting new basket trials.

The product is approved for one indication so it is now label expansion - the pricing power is amazing. This should really take off. Is it next Alexion in terms of rare disease treatment and pricing power?
๐Ÿ‘๏ธ0
Amatuer17 Amatuer17 4 years ago
Head the conf call - It was good call.

The results are much better that what PR said. Slide 14-15 shows correct numbers which were clarified by them.

Real numbers
Total patients - 31
Total BBS patients - 28
No of patients dropped - 4
Total no of patients relevant - 24

No of patients with 5%+ weight reduction - 16 = 67% that is double the number compared to combined number of 34.5%

No of patients who lost more than 10% weight - 11 out of 24 (45.8%)
Mean reduction - 14.5%

Compared to 1st approval which had few hundred population, BBS has 1000-1500 target population in US alone

This is large population for rare disease - @ $200k per year - this is a big market.

Also this is not a gene therapy - so drug is needed forever and it keeps the weight down.

Last point - All genes targeted in basket trial are in BBS category (strong or very strong relationship) so they think the basket trial results may be positive.

Cash enough till 2022. I think if stock goes down further, it will be good opportunity to buy - stock could give 50% returns from here in 6 months based on basket trial results.
๐Ÿ‘๏ธ0
Amatuer17 Amatuer17 4 years ago
Phase 3 results - BBS stat significant -AL not

Market reaction is not good. Conf call will give more info

https://finance.yahoo.com/news/rhythm-pharmaceuticals-announces-positive-topline-120000038.html
๐Ÿ‘๏ธ0
Amatuer17 Amatuer17 4 years ago
Finally - Approval

โ€œRhythm Pharmaceuticals Announces FDA Approval of IMCIVREEโ„ข(setmelanotide) as First-ever Therapy for Chronic Weight Management in Patients with Obesity Due to POMC, PCSK1 or LEPR Deficiencyโ€

Another good news - voucher that they can sell or use for next approval

โ€œWith this approval, the FDA issued a Rare Pediatric Disease Priority Review Voucher (PRV) to Rhythm. The PRV can be redeemed to receive priority review for any subsequent marketing application or sold or transferred to other companies for their programs.โ€


https://finance.yahoo.com/news/rhythm-pharmaceuticals-announces-fda-approval-123000486.html
๐Ÿ‘๏ธ0
grich1 grich1 4 years ago
Thatโ€™s a big run with PDUFA being in November. I took some profit but still in the game and will buy 100% back if reversal. Outstanding shares only @ 44M and float 30M. PT @ $33.
๐Ÿ‘๏ธ0
midastouch017 midastouch017 4 years ago
Good call!

๐Ÿ‘๏ธ0
Amatuer17 Amatuer17 4 years ago
What is happening? Looks good
๐Ÿ‘๏ธ0
midastouch017 midastouch017 4 years ago
Not so sure the last few years.

I am no US citizen, i would not like to comment
about US politics. We have enough political
unrest in my part of the globe, in Israel.

Iโ€™ve done enough DD on PSTI and RDHL

I was a heavy investor in PSTI, sold it all a few
weeks ago at a big loss, and not looking back.

RDHL, otoh is a serious company, i am sure it will
go places, high places that is.

As for RYTM, I have no funds at the moment, but
will start a position soon.

GLTY
๐Ÿ‘๏ธ0
Amatuer17 Amatuer17 4 years ago
RYTM is not cheap as it has market cap of $832 million for pre-revenue biotech - so it is richly valued.

It has 70 employees - more than many biotech at this stage but not sufficient for marketing the drug. So they have to find a partner or go with buyout.

The good news is - the co has $228 milllion plus cash and it will allow them to run till end of 2021.

They are in niche area and there is no other competition nearby. If the drug can address genetic obesity - they have 80,000 target audience in US alone.

If the drug can be tested on genetic obesity/weight loss, it will be gold mine.
๐Ÿ‘๏ธ0
pennyrich pennyrich 4 years ago
Not so sure the last few years. But what the heck.
Iโ€™m new on RYTM. Iโ€™ve done enough DD on PSTI and RDHL to hold a small 500 share stake in both. Iโ€™ll do some extra digging here because the stakes are much higher. The last 3 months havenโ€™t been bad on the other two.
GLTUA
Pr
๐Ÿ‘๏ธ0
midastouch017 midastouch017 4 years ago
Sure. A free country, isn't it?

๐Ÿ‘๏ธ0
pennyrich pennyrich 4 years ago
Can anyone play???
๐Ÿ‘๏ธ0
midastouch017 midastouch017 4 years ago
Thanks for the heads up Amatuer17,
i'll dig into it over the weekend.

๐Ÿ‘๏ธ0
Amatuer17 Amatuer17 4 years ago
Welcome to the board. Hope we all make money

This is a PDUFA based play

PDUFA date - 27th Nov

Disease - rare disease - obesity based on genetics

MOA - impacts the MC4PA gene that controls obesity and hunger. They have 4 more trials for other sub areas also in advance stage.

As per conf call - they are looking at pricing from $200k to $400k per year Patient population for this approval - around 1000

https://ir.rhythmtx.com/static-files/fd4e0919-4d82-47e0-afe3-8cd9b5151490
๐Ÿ‘๏ธ0

Your Recent History

Delayed Upgrade Clock